Type 2 Diabetes

NCT01937858
Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Official Title: The Correlation between HbA1c and Mean Blood Glucose in Patients with Diabetes and Renal Failure

Ages Eligible for Study: 18 to 90 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample

Sponsors and Collaborators
Reem Mohammad Alamoudi

Contact: Suzan Aloraibi +966-13-5910000 ext 36289 OraibiS@NGHA.MED.SA
Contact: Reem Alamoudi +966-13-8581111 ext 31504 amoudir@ngha.med.sa
NCT01978405
Study Type: Interventional
Study Design: Allocation: Randomized
End Point Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention

Official Title: Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Ages Eligible for Study: 20 to 75 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Sponsors and Collaborators
Xiang Guang-da

Contact: Xiang Guangda, MD +8602768878410 Guangda64@hotmail.com
NCT01698775
Study Type: Interventional
Study Design: Allocation: Randomized
End Point Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title: A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control

Ages Eligible for Study: ≥30 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Sponsors and Collaborators
Merck

Contact: Toll Free Number 1-888-577-8839
NCT01621178
Study Type: Interventional
Study Design: Allocation: Randomized
End Point Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease

Ages Eligible for Study: ≥18 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Sponsors and Collaborators
Eli Lilly and Company

Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY